Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001415889-13-001739
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-28 19:04:14
Reporting Period:
2013-08-26
Filing Date:
2013-08-28
Accepted Time:
2013-08-28 19:04:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1261974 Ann Mary Gray 3911 Sorrento Valley Blvd
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-08-26 5,000 $7.67 5,000 No 4 M Direct
Common Stock Acquisiton 2013-08-26 10,000 $8.49 15,000 No 4 M Direct
Common Stock Disposition 2013-08-26 5,000 $20.62 10,000 No 4 S Direct
Common Stock Disposition 2013-08-26 10,000 $20.71 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2013-08-26 5,000 $0.00 5,000 $7.67
Common Stock Stock option (right to buy) Disposition 2013-08-26 10,000 $0.00 10,000 $8.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,500 2015-04-26 No 4 M Direct
0 2018-06-12 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2013.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.55 to $20.72 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $20.75 per share, inclusive.
  4. One-third of the shares subject to the Stock Option vested and became exercisable on April 27, 2006. Thereafter, the remaining shares subject to the Stock Option vested and became exercisable in 8 equal quarterly installments.
  5. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.